Spyglass Pharma (NASDAQ:SGP) Hits New 1-Year High - What's Next?

Key Points

• Spyglass Pharma shares reached a new 52-week high, trading around $34.67 and gaining 1.4%, giving the company a market capitalization of approximately $1.14 billion.
• Analyst sentiment is generally positive: seven analysts rate the stock Buy, one rates it Hold and one rates it Sell. The consensus rating is “Moderate Buy”, with an average price target of $44.
• The company reported a quarterly loss of $0.59 per share, missing the consensus estimate of $0.48, while institutional investors—including First Light Asset Management and Affinity Asset Advisors—recently established sizable positions.

Spyglass Pharma, Inc. (NASDAQ:SGP - Get Free Report) shares reached a new 52-week high on Tuesday. The stock traded as high as $34.24 and last traded at $34.6730, with a volume of 1,557 shares traded. The stock had previously closed at $33.64.

Analyst Ratings Changes

SGP has been the subject of several research analyst reports. Weiss Ratings lowered shares of Spyglass Pharma from a "sell (e+)" rating to a "sell (e)" rating in a report on Friday, September 25th. Raymond James Financial started coverage on shares of Spyglass Pharma in a research report on Friday, August 14th. They issued an "outperform" rating and a $39.00 price objective for the company. UBS Group reaffirmed a "buy" rating on shares of Spyglass Pharma in a research note on Monday, October 5th. HC Wainwright reiterated a "buy" rating and set a $37.00 target price on shares of Spyglass Pharma in a report on Wednesday, October 21st. Finally, Wall Street Zen raised Spyglass Pharma from a "sell" rating to a "hold" rating in a research note on Saturday. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $44.00.

Spyglass Pharma Stock Up 1.4%

The firm has a market capitalization of $1.14 billion and a P/E ratio of -4.91. The stock has a fifty day moving average of $27.37 and a 200-day moving average of $24.32.

Spyglass Pharma (NASDAQ:SGP - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.11). Sell-side analysts predict that Spyglass Pharma, Inc. will post -2.55 EPS for the current fiscal year.

Institutional Trading of Spyglass Pharma

Institutional investors have recently made changes to their positions in the business. Bank of New York Mellon Corp bought a new position in Spyglass Pharma in the second quarter valued at $533,000. Bank of America Corp DE acquired a new stake in Spyglass Pharma in the 1st quarter valued at $726,000. First Light Asset Management LLC bought a new stake in Spyglass Pharma during the 1st quarter worth about $9,716,000. Affinity Asset Advisors LLC bought a new stake in Spyglass Pharma during the 1st quarter worth about $6,478,000. Finally, Monashee Investment Management LLC bought a new stake in Spyglass Pharma during the 1st quarter worth about $2,461,000.

Spyglass Pharma Company Profile

SpyGlass Pharma, Inc is an ophthalmic pharmaceutical company developing sustained drug-delivery technologies for the treatment of eye diseases. The company's platform is designed to provide continuous delivery of medication within the eye, with the goal of reducing reliance on daily topical eye drops and improving treatment adherence.

SpyGlass Pharma's lead product candidate is an investigational drug-delivery system intended to treat glaucoma and ocular hypertension. The implant is designed to be placed in the eye during cataract surgery and release a therapeutic agent over an extended period, potentially providing longer-term control of elevated intraocular pressure.

The company is advancing its technology through clinical development and regulatory processes in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.